SSCRIPTURAclinical · decision · supportScriptura
Sign in
Patient sign inClinician sign in

Clinician reference, evidence review

Tirzepatide

Mounjaro, Zepbound

Dual GIP and GLP-1 receptor agonist, FDA approved

Reviewed by: Sabrina Runbeck, PA-C, MHS, MPH, Co-Founder, Scriptura Health. Physician assistant, public health master's, health sciences master's. Sabrina reviews the clinical layer of Scriptura Health, and she reviews every compound reference on this site.

Published: 2026-07-08. This page is an evidence review, not clinical instruction, and does not recommend dosing, cadence, routes, or prescribing decisions. Prescribing is the responsibility of a licensed clinician evaluating a specific patient.

Regulatory posture

Tirzepatide is FDA approved and marketed as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management. Because an FDA approved product is commercially available, compounding is tightly restricted and generally allowed only under narrow, defined circumstances. It is not a controlled substance under the DEA.

Mechanism, plain English

Tirzepatide activates two gut hormone receptors at once: GLP-1 and GIP, both of which help control blood sugar and appetite. By acting on both, it helps the body release insulin appropriately, reduces hunger, and slows stomach emptying. The dual action is associated with strong effects on blood sugar and body weight in trials.

Evidence landscape

Tirzepatide is backed by large Phase 3 randomized controlled trials that report substantial weight loss and glucose lowering. The SURMOUNT-1 trial showed large, dose-dependent weight reduction in adults with obesity who did not have diabetes. A systematic review and meta-analysis of randomized trials found tirzepatide to be effective for weight loss with a safety profile dominated by gastrointestinal side effects. A head-to-head randomized trial reported greater average weight loss with tirzepatide than with semaglutide for the treatment of obesity, giving clinicians direct comparative data. Longer term cardiovascular outcome data continue to accumulate, and nausea and other gastrointestinal effects remain the most frequently reported tolerability issues.

Primary PubMed citations

  1. Tirzepatide Once Weekly for the Treatment of Obesity , Jastreboff AM et al, New England Journal of Medicine, 2022. PMID: 35658024
  2. Tirzepatide as a novel effective and safe strategy for treating obesity: a systematic review and meta-analysis of randomized controlled trials , Cai W et al, Frontiers in Public Health, 2024. PMID: 38356942
  3. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity , Aronne LJ et al, New England Journal of Medicine, 2025. PMID: 40353578

Citations selected from the PubMed literature. Every URL was checked at publication time. Scriptura's daily PubMed scan surfaces new studies for each compound as they index. See the regulatory and literature layers on the demo.

Scope of this page

This is a plain English summary of the peer reviewed literature and current regulatory posture. It is not a substitute for a licensed clinician's judgment on a specific patient. It does not recommend dosing, cadence, or route. Where the literature is limited or preclinical, this page says so, so a prescriber can weigh marketing claims against what the trials actually show.

More clinician references

  • BPC-157 , Cytoprotective peptide, research grade, not FDA approved
  • TB-500 , Regenerative peptide, research grade, not FDA approved
  • Semaglutide , GLP-1 receptor agonist, FDA approved
  • Retatrutide , Triple GIP, GLP-1, and glucagon receptor agonist, investigational, not FDA approved
  • CJC-1295 , Growth hormone releasing hormone analog, research grade, not FDA approved
  • Ipamorelin , Growth hormone secretagogue, research grade, not FDA approved
  • Sermorelin , Growth hormone releasing hormone analog, research grade, not currently FDA marketed
  • Tesamorelin , Growth hormone releasing hormone analog, FDA approved
  • Thymosin Alpha-1 , Immunomodulatory peptide, not FDA approved in the US, orphan drug status

Want the evidence layer for your practice.

A daily one page regulatory brief and a plain English PubMed literature delta, in your Drive every morning. No prescribing, no dispensing, no pharmacy routing. Just the evidence and regulatory read a prescriber wants before writing the next protocol.

Book a demoRequest access
Tirzepatide clinician reference: evidence review and regulatory posture | Scriptura Health | Scriptura Health